US Stock MarketDetailed Quotes
AIM AIM ImmunoTech
- 0.2738
- +0.0039+1.44%
Close Aug 14 16:00 ET
15.64MMarket Cap-427P/E (TTM)
0.2800High0.2650Low119.58KVolume0.2650Open0.2699Pre Close32.55KTurnover0.23%Turnover RatioLossP/E (Static)57.14MShares0.695352wk High3.80P/B14.40MFloat Cap0.251152wk Low--Dividend TTM52.58MShs Float836.0000Historical High--Div YieldTTM5.56%Amplitude0.2511Historical Low0.2720Avg Price1Lot Size
AIM ImmunoTech Stock Forum
Sign in to post a comment
$AIM ImmunoTech (AIM.US)$ Aim Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
1
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces First Dose Level Is Generally Well-Tolerated in Phase 1B/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
5
$AIM ImmunoTech (AIM.US)$
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
NEWS
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM ImmunoTech Inc. announced promising interim data showing that combining Ampligen with Keytruda in treating recurrent ovarian cancer could have a powerful synergistic effect, significantly increasing response rates and progression-free survival. The study also highlighted increased an...
2
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
4
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions 2 MINUTES AGO, 8:50 AM EST VIA GLOBENEWSWIRE![]()
1
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer 3 MINUTES AGO, 9:10 AM EST VIA GLOBENEWSWIRE![]()
$AIM ImmunoTech (AIM.US)$ AIM ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca's Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer![]()
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
HotShot369 OP : Ignore the aztr. sold some for profit and dilute cost went down
HotShot369 OP : Some of these plan to hold for a few days to 2 weeks
HotShot369 OP : now just realized I got posted everywhere I bought. WHAT THE FLIP
HotShot369 OP : I'm also watching rnaz
HotShot369 OP : mbio too
View more comments...